Spectral Medical Inc. (EDT.TO)
| Previous Close | 0.4450 |
| Open | 0.4350 |
| Bid | 0.4300 x 0 |
| Ask | 0.4400 x 0 |
| Day's Range | 0.4350 - 0.4450 |
| 52 Week Range | 0.2250 - 0.6700 |
| Volume | |
| Avg. Volume | 84,670 |
| Market Cap | 121.181M |
| Beta (5Y Monthly) | 0.91 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings Date | N/A |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | Dec 19, 2011 |
| 1y Target Est | N/A |
- GlobeNewswire
Spectral Medical Provides Tigris Trial Update
101 patients enrolled TORONTO, April 10, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today provided an update on the Company’s Tigris trial, a Phase 3 follow-on study evaluating the use of Polymyxin B Hemoperfusion (“PMX”) in a randomized controlled trial of adults treated for endotoxemia and septic shock. Enrollment: Robust enrollment activity continues throug
- GlobeNewswire
Spectral Medical Chair to Retire From the Board of Directors
Dr. Paul Walker to succeed as ChairTORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced that Anthony (Tony) Bihl III, Spectral’s Chairman, will be retiring from the Board at Spectral’s upcoming Shareholder Meeting in June 2024. Mr. Bihl has been a Director of the Company for 16 years and was appointed to the role of Chairman in 2010. M
- GlobeNewswire
Spectral Medical Announces Fourth Quarter and Fiscal 2023 Results and Provides Corporate Update
97 patients enrolledTORONTO, March 28, 2024 (GLOBE NEWSWIRE) -- Spectral Medical Inc. (“Spectral” or the “Company”) (TSX: EDT), a late-stage theranostic company advancing therapeutic options for sepsis and septic shock, today announced its financial results for the fourth quarter and for the year ended December 31, 2023 and provided a corporate update. The Company made significant progress throughout 2023, both clinically and operationally. Specifically, regarding its Tigris trial, a Phase III c
